Scholarlink

Background <p>Breast cancer remains a leading cause of cancer-related death among females, with triple-negative breast cancer (TNBC) posing significant therapeutic challenges due to its aggressive behavior and lack of targeted treatments. Mefloquine (MEF), an antimalarial agent, exhibits anticancer activity by disrupting lysosomal function and enhancing ROS-mediated apoptosis. Cisplatin (CIS) induces apoptosis but is limited by drug resistance. This study investigates the combined effects of MEF, in both free and niosomal forms, and CIS on apoptosis and angiogenesis in breast cancer cells.</p> Methods <p>The cytotoxicity of MEF, CIS, and their combinations was assessed in MCF-7 and TNBC cell lines using MTT assays. Gene expression and ELISA analysis confirmed significant upregulation of pro-apoptotic markers <i>Bax</i> (<i>p</i> &lt; 0.001) and <i>CASP3</i> (<i>p</i> &lt; 0.001), and downregulation of anti-apoptotic Bcl-2 (<i>p</i> &lt; 0.001) and angiogenic factors <i>VEGF</i> and <i>KDR</i>. Molecular docking studies (Molegro Virtual Docker) evaluated binding affinities of MEF and CIS to BAX, Bcl-2, and VEGFR. NMEF was prepared and characterized for stability and encapsulation efficiency.</p> Results <p>NMEF demonstrated high encapsulation efficiency (87.21%) and was stable over six months. Combination treatments, particularly Cisplatin-niosomal Mefloquine (CIS-NMEF), showed synergistic cytotoxicity (CI &lt; 1) and significantly lower IC50 values in both cell lines (TNBC: 2.30&#xa0;µg/ml). Molecular docking revealed strong binding affinities for CIS-NMEF with BAX (-139.72), Bcl-2 (-136.09), and VEGFR (-139.19). Gene expression analysis confirmed upregulation of pro-apoptotic markers (<i>Bax</i>, <i>CASP3</i>) and downregulation of anti-apoptotic *Bcl-2* and angiogenic factors (<i>VEGF</i>, <i>KDR</i>). ROS production increased significantly in combination groups, indicating enhanced oxidative stress.</p> Conclusion <p>The niosomal formulation of MEF synergistically enhances CIS efficacy by promoting apoptosis, and suppressing angiogenesis in TNBC. These findings highlight NMEF as a promising chemosensitizer to overcome cisplatin resistance. Future studies should focus on in vivo validation and clinical translation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Niosomal mefloquine and cisplatin in breast cancer: comparative effects on apoptosis and angiogenesis via in vitro and in silico analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Zohreh Salari,
  • Ahmad Khosravi,
  • Arezo Riahi,
  • Elaheh Molaakbari,
  • Ehsan Salarkia,
  • Ali Reza Keyhani,
  • Samira Sohbati,
  • Ghazal Mansouri,
  • Mina Khosravi,
  • Mohammad Zarif,
  • Mohammad Amin Raeisi Estabragh

摘要

Background

Breast cancer remains a leading cause of cancer-related death among females, with triple-negative breast cancer (TNBC) posing significant therapeutic challenges due to its aggressive behavior and lack of targeted treatments. Mefloquine (MEF), an antimalarial agent, exhibits anticancer activity by disrupting lysosomal function and enhancing ROS-mediated apoptosis. Cisplatin (CIS) induces apoptosis but is limited by drug resistance. This study investigates the combined effects of MEF, in both free and niosomal forms, and CIS on apoptosis and angiogenesis in breast cancer cells.

Methods

The cytotoxicity of MEF, CIS, and their combinations was assessed in MCF-7 and TNBC cell lines using MTT assays. Gene expression and ELISA analysis confirmed significant upregulation of pro-apoptotic markers Bax (p < 0.001) and CASP3 (p < 0.001), and downregulation of anti-apoptotic Bcl-2 (p < 0.001) and angiogenic factors VEGF and KDR. Molecular docking studies (Molegro Virtual Docker) evaluated binding affinities of MEF and CIS to BAX, Bcl-2, and VEGFR. NMEF was prepared and characterized for stability and encapsulation efficiency.

Results

NMEF demonstrated high encapsulation efficiency (87.21%) and was stable over six months. Combination treatments, particularly Cisplatin-niosomal Mefloquine (CIS-NMEF), showed synergistic cytotoxicity (CI < 1) and significantly lower IC50 values in both cell lines (TNBC: 2.30 µg/ml). Molecular docking revealed strong binding affinities for CIS-NMEF with BAX (-139.72), Bcl-2 (-136.09), and VEGFR (-139.19). Gene expression analysis confirmed upregulation of pro-apoptotic markers (Bax, CASP3) and downregulation of anti-apoptotic *Bcl-2* and angiogenic factors (VEGF, KDR). ROS production increased significantly in combination groups, indicating enhanced oxidative stress.

Conclusion

The niosomal formulation of MEF synergistically enhances CIS efficacy by promoting apoptosis, and suppressing angiogenesis in TNBC. These findings highlight NMEF as a promising chemosensitizer to overcome cisplatin resistance. Future studies should focus on in vivo validation and clinical translation.